Quantcast

Latest Hedgehog signaling pathway Stories

2009-05-22 08:52:09

A researcher of the University of Innsbruck elucidates an important developmental mechanism It is the concentration of a few signaling molecules that determines the fate of individual cells during the early development of organisms. In the renowned journal Current Biology, a team of molecular biologists led by Pia Aanstad of the University of Innsbruck reports that a variety of molecular mechanisms accounts for the interpretation of the concentration of the signaling molecule Hedgehog. The...

2009-02-19 08:53:35

Researchers at Worcester Polytechnic Institute have identified the function of a protein that sticks out of the embryonic cell membrane like an antenna and processes signals needed for proper wing development in fruit fliesIn their ongoing study of the processes involved in embryonic development in fruit flies, researchers at WPI's Life Sciences and Bioengineering Center at Gateway Park have identified the function of a protein that sticks out of the embryonic cell membrane like an antenna...

2008-10-28 00:00:19

U.S. researchers said brain tumors appear to more aggressive when they feed off cancer stem cells that use Sonic Hedgehog protein signaling mechanisms. The researchers said the finding could help in the development of treatments that kill malignant brain tumors at their source and prevent them from recurring, Cedars-Sinai Medical Center said Monday. The study, conducted by Cedars Sinai's Maxine Dunitz Neurosurgical Institute, identified a subset of brain tumor stem cells that are...

2008-10-23 09:00:38

Curis, Inc. (NASDAQ: CRIS), a drug development company focused on developing the next generation of proprietary targeted medicines for cancer treatment, today announced that the Company will be presenting at the 7th Annual BIO Investor Forum Conference, at 3:45 p.m. local time (6:45 p.m. EDT) on October 30, 2008, at the Palace Hotel in San Francisco, California. Daniel R. Passeri, Curis' President and Chief Executive Officer, will provide an overview of the status of GDC-0449, an...

2008-10-21 09:00:53

Curis, Inc. (NASDAQ:CRIS), a drug development company focused on developing proprietary targeted medicines primarily for cancer treatment, today announced that the Company will release its second quarter financial results on Tuesday, October 28, 2008 before the market opens. The Company will also hold a conference call on the same day at 10:00 A.M. Eastern time to discuss: (i) its Hedgehog antagonist program under collaboration with Genentech, (ii) CUDC-101, CUDC-305 and other proprietary...

2008-10-16 09:00:42

Curis, Inc. (NASDAQ: CRIS), a drug development company focused on developing the next generation of proprietary targeted medicines for cancer treatment, today announced that the Company will be presenting at the 2008 Boston Biotech R&D Conference, at 9:00 a.m. EDT on October 22, 2008, at Harvard Medical School in Cambridge, Mass. Daniel R. Passeri, Curis' President and Chief Executive Officer, will provide an overview of the status of GDC-0449, an orally-administered small molecule...

2008-10-16 06:00:31

CAMBRIDGE, Mass., Oct. 16, 2008 (GLOBE NEWSWIRE) -- Infinity Pharmaceuticals, Inc. (Nasdaq:INFI), an innovative cancer drug discovery and development company, today announced that it has initiated a Phase 1 clinical trial of its oral Hedgehog signaling pathway inhibitor, IPI-926, in patients with advanced and/or metastatic solid tumors. IPI-926 is a novel, proprietary inhibitor of the Hedgehog signaling pathway. It is a derivative of the natural product cyclopamine that binds to and...

2008-08-28 09:01:23

Curis, Inc. (NASDAQ: CRIS), a drug development company focused on developing the next generation of proprietary targeted medicines for cancer treatment, today announced that its collaborator Genentech, Inc. has indicated that it expects to initiate a Phase II clinical trial of GDC-0449, an orally-administered small molecule Hedgehog antagonist, as a maintenance therapy for ovarian cancer patients in second or third complete remission. Genentech is developing GDC-0449 under a collaboration...

2008-08-27 15:01:10

Curis, Inc. (NASDAQ: CRIS), a drug development company focused on developing next generation proprietary targeted medicines for cancer treatment, today announced the publication of preclinical data in Nature that support the premise that Hedgehog proteins play an important role in supporting tumor growth in Hedgehog-expressing solid tumors through a paracrine mechanism of action. The paper reported that analysis of human tissue samples by Genentech scientists revealed that subsets of...

2008-08-26 09:01:20

Curis, Inc. (NASDAQ: CRIS), a drug development company focused on developing next generation proprietary targeted medicines for cancer treatment, today announced that the first patient has been treated in a Phase I clinical trial of CUDC-101, a first-in-class small molecule drug candidate that has been designed as an inhibitor of epidermal growth factor receptor (EGFR), epidermal growth factor receptor 2 (Her2) and histone deacetylase (HDAC). CUDC-101 has been designed to simultaneously...


Word of the Day
drawcansir
  • A blustering, bullying fellow; a pot-valiant braggart; a bully.
This word is named for Draw-Can-Sir, a character in George Villiers' 17th century play The Rehearsal.
Related